P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs

Authors:

Abstract
P2Y12 antagonists are the standard in antiplatelet therapy but their potential effects on functional myocardial recovery and cardioprotection post-myocardial infarction (MI) are unknown. We investigated in a preclinical model of MI whether ticagrelor and clopidogrel differently affect cardiac repair post-MI. Pigs either received: 1) clopidogrel (600mg; 75mg/qd); ticagrelor (180mg; 90mg/bid); and 3) placebo-control. MI was induced by mid-left anterior descending coronary artery balloon occlusion (60min) and animals received the maintenance doses for the following 42days. Serial cardiac magnetic resonance was performed at day3 and day42 for the assessment of global and regional cardiac parameters. We determined cardiac AMP-activated protein kinase (AMPK), Akt/PKB, aquaporin-4, vascular density and fibrosis. In comparison to controls, both P2Y12 antagonists limited infarct expansion at day3 although ticagrelor induced a further 5% reduction (p < 0.05 vs. clopidogrel) whereas edema was only reduced by ticagrelor (≈23% p < 0.05). Scar size decreased at day42 in ticagrelor-treated pigs vs. controls but not in clopidogrel-treated pigs. Left ventricular ejection fraction was higher 3days post-MI in ticagrelor-treated pigs and persisted up to day42 (p < 0.05 vs. post-MI). Regional analysis revealed that control and clopidogrel-treated pigs had severe and extensive wall motion abnormalities in the jeopardized myocardium and a reduced myocardial viability that was not as evident in ticagrelor-treated pigs (χ2 p < 0.05 vs. ticagrelor). Only ticagrelor enhanced myocardial AMPK and Akt/PKB activation and reduced aquaporin-4 levels (p < 0.05 vs. control and clopidogrel). No differences were observed in vessel density and fibrosis markers among groups. Ticagrelor is more efficient than clopidogrel in attenuating myocardial structural and functional alterations post-MI and in improving cardiac healing. These benefits are associated with persistent AMPK and Akt/PKB activation.
Funding Information
  • PNS (SAF2016-76819-R)
  • PNS (2015-71653-R)
  • Spanish Ministry of Science and Innovation
  • FEDER
  • Instituto de Salud Carlos III CIBERCV (CN16/11/00411)
  • Muy Ilustrísima Administración
  • Hospital de la Santa Creu I Sant Pau
  • AstraZeneca
  • Generalitat of Catalunya (2014SGR1303)
  • Fundacion Investigación Cardiovascular

This publication has 40 references indexed in Scilit: